Ovarian Cancer Treatment in Hyderabad
Reviewed May 2026 · Dr. Madhav Danthala
Ovarian cancer is the gynaecologic cancer most often caught late — because there is no Pap-smear-equivalent screening test for the general population. The signal that matters is persistent bloating. Dr. Madhav Danthala provides treatment planning, chemotherapy, PARP inhibitors, and second opinions at KIMS-Sunshine Hospitals, Begumpet, and Peoples Polyclinic, Manikonda.
When to See a Doctor
Most causes of bloating and pelvic discomfort are benign. The pattern that matters is persistence — symptoms that are new, last more than three weeks, and happen most days.
Dr. Danthala's Approach
Ovarian cancer treatment in 2026 is increasingly molecularly guided. Three principles shape every consultation.
-
BRCA and HRD profiling first
Every advanced ovarian cancer should be tested for BRCA mutation and HRD status at diagnosis to identify candidates for PARP-inhibitor maintenance.
-
More than one path
For advanced disease, primary surgery vs neoadjuvant chemotherapy followed by interval surgery are both defensible — depending on disease spread and patient fitness.
-
Clear, structured communication
Every consult ends with a written summary of options, expected timelines, and the trade-offs each plan carries.
Treatment Options
Ovarian cancer is treated with a combination of surgery, chemotherapy, and increasingly, molecularly-guided maintenance therapy. The order — surgery first or chemotherapy first — is shaped by tumour spread and patient fitness. Below are the major modalities.
Cytoreductive (debulking) surgery — goal is R0
For most ovarian cancers, the goal of surgery is complete cytoreduction (R0 — no visible residual disease). This typically involves total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, lymphadenectomy, and resection of any peritoneal implants. Primary surgery is preferred when complete resection is achievable; otherwise, neoadjuvant chemotherapy followed by interval debulking is the alternative.
Carboplatin + paclitaxel — six cycles
Platinum-based chemotherapy (carboplatin combined with paclitaxel) is the backbone for most epithelial ovarian cancers, given over six cycles. For advanced disease, intraperitoneal chemotherapy (IP) and HIPEC (heated intraperitoneal chemotherapy at the time of surgery) are options in selected centres. Sensitivity to platinum (platinum-free interval > 6 months) shapes choices at recurrence.
Olaparib, niraparib, rucaparib — game-changers
PARP inhibitors as maintenance therapy after platinum-based chemotherapy have transformed outcomes — particularly for BRCA-mutated and HRD-positive disease. Olaparib is the first-line standard for BRCA+ patients (SOLO-1 trial). Niraparib has broader applicability across HRD status. Maintenance is typically given for two years and meaningfully extends progression-free survival.
Bevacizumab, mirvetuximab, hormonal therapy
Bevacizumab (anti-VEGF) added to chemotherapy and continued as maintenance is an option for HRD-negative or non-BRCA-mutated disease. Mirvetuximab soravtansine is approved for folate-receptor-alpha-positive platinum-resistant disease. Hormonal therapy (letrozole) plays a role in low-grade serous ovarian cancer. Trials of immunotherapy and antibody-drug conjugates continue to expand options.
Treatment is shaped by stage, BRCA/HRD status, fitness, and patient preference. The list above is the menu. The right plan is built with the patient in the room.
Frequently Asked Questions
Is there a screening test for ovarian cancer?
For average-risk women, no. The Pap smear catches cervical cancer, the mammogram catches breast — but for ovarian, no equivalent test works for the general population. This is why ovarian cancer is most often caught late. For high-risk women (BRCA carriers), surveillance with TVUS and CA-125 is offered.
What are the warning signs?
Persistent bloating, pelvic or abdominal pain, feeling full quickly, and urinary urgency. The pattern that matters is when they are new, last more than three weeks, and happen most days.
Should I get BRCA testing?
BRCA1 and BRCA2 mutations significantly raise lifetime ovarian and breast cancer risk. Testing is recommended for personal or family history of breast or ovarian cancer (especially before age 50), male breast cancer in the family, or known BRCA mutation in a relative. For confirmed carriers, integrated screening covers both ovarian (TVUS + CA-125) and breast (annual MRI + mammogram); risk-reducing surgery is also discussed.
What is a PARP inhibitor?
PARP inhibitors (olaparib, niraparib, rucaparib) are oral targeted therapies particularly effective in BRCA-mutated or HRD-positive ovarian cancers. Used as maintenance therapy after chemotherapy. Significantly improve outcomes for selected patients.
What does treatment usually involve?
Surgery (debulking) combined with platinum-based chemotherapy. Order depends on tumour spread and patient fitness. Maintenance with PARP inhibitors or anti-VEGF agents is often added based on molecular profile.
About Dr. Madhav Danthala
Dr. Madhav Danthala is a medical oncologist and hemato-oncologist practising at KIMS-Sunshine Hospitals, Begumpet and Peoples Polyclinic, Manikonda, Hyderabad. His clinical interests span breast, lung, gastrointestinal, gynaecologic, and head & neck cancers, with a focus on subtype-led treatment planning, second opinions, and shared decision-making. He has trained at premier oncology institutes and performed 300+ stem cell transplants.
Trusted guidelines & further reading
- ESMO — Cancer Guides for Patients European Society for Medical Oncology patient guides — freely accessible, evidence-based.
- ASCO / Cancer.Net — Ovarian, Fallopian Tube & Peritoneal American Society of Clinical Oncology patient education portal.
- NCI / Cancer.gov — Ovarian, Fallopian Tube, Peritoneal US National Cancer Institute clinical treatment summaries.
From our blog
- Your Mother's Medical History Is Your Screening Map Ovarian cancer is the gynaecologic cancer where BRCA testing changes the most — and family history is how that conversation begins.
- The Two-Oncologist Rule: When to Get a Second Opinion For ovarian cancer, the choice between primary debulking and neoadjuvant chemotherapy benefits from a second perspective.